CALGARY, Aug. 30 /CNW/ - Stem Cell Therapeutics Corp. (TSX-V:SSS), a Canadian biotechnology company engaged in treating certain central nervous system disorders by stimulating endogenous neural stem cells, announced today the release of a video interview with Dr. Steven Cramer, the Principal Investigator of the company’s Phase IIa clinical trial. In the interview Dr. Cramer, a leading stroke specialist at the University of California, Irvine, discusses his views on the company’s lead therapy, NTx(TM)-265, in development with regard to its potential benefit to patients suffering recent stroke. NTx(TM)-265 is a candidate treatment regimen comprised of human chorionic gonadotropin (hCG) and erythropoietin (EPO) administered systemically.
